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Abstract
Background: Immunization with recombinant carboxyl-terminal domain of the heavy chain (Hc domain) of 
botulinum neurotoxin (BoNT) stimulates protective immunity against native BoNT challenge. Most studies developing 
a botulism vaccine have focused on the whole Hc; however, since the principal protective epitopes are located within 
β-trefoil domain (Hcβtre), we hypothesize that immunization with the Hcβtre domain is sufficient to confer protective 
immunity. In addition, enhancing its uptake subsequent to nasal delivery prompted development of an alternative 
vaccine strategy, and we hypothesize that the addition of targeting moiety adenovirus 2 fiber protein (Ad2F) may 
enhance such uptake during vaccination.
Results: The Hcβtre serotype B immunogen was genetically fused to Ad2F (Hcβtre/B-Ad2F), and its immunogenicity 
was tested in mice. In combination with the mucosal adjuvant, cholera toxin (CT), enhanced mucosal IgA and serum 
IgG Ab titers were induced by nasal Hcβtre-Ad2F relative to Hcβtre alone; however, similar Ab titers were obtained 
upon intramuscular immunization. These BoNT/B-specific Abs induced by nasal immunization were generally 
supported in large part by Th2 cells, as opposed to Hcβtre-immunized mice that showed more mixed Th1 and Th2 
cells. Using a mouse neutralization assay, sera from animals immunized with Hcβtre and Hcβtre-Ad2F protected mice 
against 2.0 LD50.
Conclusion: These results demonstrate that Hcβtre-based immunogens are highly immunogenic, especially when 
genetically fused to Ad2F, and Ad2F can be exploited as a vaccine delivery platform to the mucosa.
Background
Clostridium botulinum is a Gram-positive, spore-forming
anaerobe commonly found in soil, and is responsible for
production of botulinum neurotoxin (BoNT), a potent
lethal toxin [1]. Seven BoNT serotypes (A-G) have been
identified [2]: serotypes A, B, E, and F are primarily
responsible for human botulism; serotypes C and D are
mostly limited to intoxication of animals [3]; and host
specificity for serotype G has not been fully determined
[4]. Three clinical manifestations are related to naturally
acquired botulism: foodborne, infant, and wound botu-
lism [5]. However, recently, three other forms have been
described [6]: undefined or adult intestinal, inadvertent
injection-related and inhalational botulism. All forms of
BoNT intoxication present with the same clinical syn-
drome of symmetrical and descending flaccid paralysis of
motor and autonomic nerves, which can cause respira-
tory arrest and death [7,8]. Since natural exposure to C.
botulinum spores is rare, the necessity to create a vaccine
is primarily for high-risk individuals. Moreover, an inten-
tional release to contaminate food and water supplies or
for use as an aerosolized weapon [3] warrants the devel-
opment of vaccines to protect high-risk groups.
Currently, there are no certified vaccines for preventing
human botulism. In the United States, an investigational
pentavalent botulinum toxoid that includes serotypes A
through E is used to vaccinate high risk individuals [9].
Although toxoid-based vaccines can be conveniently pro-
duced, these have a number of limitations, including iso-
lation of active toxins, loss of essential neutralizing
epitopes by formalin treatment, and multiple immuniza-
tions required to sustain elevated Ab titers [10]. To over-
come these limitations, recent efforts have shifted to
adapting recombinant BoNT heavy (H) chain to develop
subunit vaccines [11,12], as well as employing DNA vac-
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reliance on handling active intact BoNTs.
BoNTs are originally produced as 150 kDa chains that
are post-translationally nicked into a C-terminal H chain
(ca. 100 kDa) and N-terminal light (L) chain (ca. 50 kDa)
[13]. Functionally, the toxins contain three domains [15]:
a receptor-binding domain, a translocation domain, and
an enzymatic domain. Part of the receptor-binding
domain is located in the carboxyl-terminal segment of
the H chain, a region referred as the fragment C or Hc.
The amino-terminal segment of the H chain is responsi-
ble for the translocation and internalization of the L chain
into the cell [16]. The L chain acts as a zinc-dependent
endoprotease, which selectively attacks three crucial pro-
teins, disabling the docking and fusion of acetylcholine-
containing synaptic vesicles to the plasma membrane
[17].
A number of studies [rev. in [9]] have reported that
recombinant 50 kDa Hc domain possesses the ability to
stimulate protective Abs capable of neutralizing native
BoNT. The Hc is an effective immunogen and simultane-
ously capable of binding and penetrating epithelial barri-
ers in the gut and airway, suggesting that this molecule
could be used as a mucosal vaccine against botulism [18].
The crystal structure of BoNT shows that the Hc frag-
ment is composed of two subdomains: N-terminal devel-
oping jelly roll motif and a C-terminal forming β-trefoil
domain [19,20]. The β-trefoil motif, especially the final
approximately 150 residues, significantly diverges among
serotypes with sequence similarity as low as 15% [21], but
maintains a ganglioside binding motif that is conserved
[22]. Since there is a lack of significant cross-reactivity
among the serotypes, it is speculated that the protective
epitopes are located within this fragment of Hc. In our
previous study, vaccination with the Hc β-trefoil domain,
referred to as Hcβtre/A, rather than the intact Hc, was
shown to protect against BoNT/A [23].
A major impediment in forwarding mucosal vaccines
into humans is the absence of mucosal adjuvants suitable
for human use. Significant efforts have focused on live,
attenuated vaccine approaches to circumvent the require-
ment for exogenous adjuvants. One such vaccine vector
has been a modified adenovirus widely tested for a num-
ber of experimental vaccines [24]. A major benefit of ade-
noviral vectors is their affinity for the mucosal
epithelium, which makes them optimal for mucosal vac-
cination [25], although this may be problematic for use in
humans because of pre-existing Abs [26]. Initial attach-
ment of adenovirus to the host cell surface via coxsackie-
adenovirus receptor is mediated by the knob domain of
adenovirus fiber [27]. To circumvent use of a live vector,
the adenovirus 2 fiber (Ad2F) protein was selected and
tested for its abilities to deliver BoNT/B Hcβtre vaccine.
Previously, immunization with the fusion protein,
Hcβtre/A-Ad2F, increased onset of plasma and mucosal
Ab responses and conferred protection against BoNT/A
[23]. In light of these findings, we queried whether this
approach could be adapted to generate a vaccine for
BoNT/B. Thus, Hcβtre/B was genetically fused to Ad2F,
and immunization with Hcβtre/B-Ad2F was found to be
more immunogenic than Hcβtre alone, further suggesting
the utility of Ad2F as a targeting moiety to improve a
mucosal vaccine's immunogenicity.
Results
Comparison of Ab responses by Hcβtre-or Hcβtre-Ad2F-
vaccinated mice
Groups of mice were immunized by the intranasal (i.n.)
route with either Hcβtre or Hcβtre-Ad2F to assess the
ability of each to evoke a mucosal and systemic immune
response (Figure 1A,B). In parallel experiments, mice
were given the same vaccines, but via the i.m. route (Fig-
ure 1C,D). All mice were boosted on days 7 and 14.
Serum and fecal samples were collected at weekly inter-
vals beginning on day 14 until day 35 post-primary
immunization and then evaluated for anti-Hcβtre Ab
titers by standard ELISA methods. Significant S-IgA Ab
responses were detected in fecal extracts from mice
dosed nasally with Hcβtre-Ad2F, either in the presence or
absence of CT adjuvant, as opposed to mice dosed nasally
with Hcβtre, which produced weak Hcβtre-specific S-IgA
Abs (Figure1A). The intramuscular (i.m.) Hcβtre-Ad2F-
immunized mice also exhibited elevated fecal Hcβtre-
specific S-IgA Ab titers, but these tended to wane at the
later time points (Figure 1C). In the presence of an adju-
vant, i.n. (Figure 1B) and i.m. immunization (Figure 1D)
with Hcβtre-Ad2F and Hcβtre induced elevated serum
IgG Abs. Although mice i.n. immunized with Hcβtre-
Ad2F alone or i.m. or i.n. with Hcβtre alone exhibited
only weak serum IgG responses (Figure 1B,D), mice i.m.
immunized with Hcβtre-Ad2F without CT showed mod-
est induction of serum IgG Ab responses (Figure 1D).
To assess whether S-IgA anti-Hcβtre Abs were induced
in nasal secretions, nasal wash samples collected on day
35 post-primary immunization showed significantly ele-
vated S-IgA Abs in those mice immunized i.n. with
Hcβtre-Ad2F plus CT when compared with mice given
adjuvanted Hcβtre (Figure 2A). Mice dosed with the vac-
cines, but without adjuvant, showed no S-IgA Abs in
their nasal washes (Figure 2A). Sera from the immunized
mice were also evaluated for the induced IgG subclass
responses from the CT co-immunized mice (Figure
2B,C). Both groups of i.n.-immunized mice showed eleva-
tions in their IgG1, IgG2a, and IgG2b anti-Hcβtre
responses, but only the Hcβtre-Ad2F plus CT-immu-
nized mice showed significant elevations in IgG1
responses (p ≤ 0.001) (Figure 2B). In contrast, the i.m.
Hcβtre-Ad2F plus CT-immunized mice showed signifi-
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Hcβtre responses compared to the i.m. Hcβtre plus CT-
immunized mice, and both groups showed equivalent
IgG2b responses (Figure 2C). These results clearly show
that Hcβtre evokes both mucosal and systemic immune
Ab responses influenced by route of immunization, and
the Ab titers are significantly improved when Hcβtre is
genetically fused to Ad2F.
Distribution of immune B cells following i.n. or i.m. 
immunization
To learn the source of the immune Abs obtained upon
immunization with Hcβtre-based vaccines, Ag-specific B
cell responses from the various mucosal and systemic
lymphoid tissues were measured using an Ab ELISPOT
assay. Ag-specific Ab-forming cells (AFCs) were mini-
mally detected in lymphoid tissues of mice vaccinated
without CT (data not shown). Elevated Hcβtre-specific
IgA AFCs were detected in nasal-associated lymphoretic-
ular tissue (NALT) (p ≤ 0.001) and nasal passages (NPs)
(p ≤ 0.05) from mice i.n. immunized with Hcβtre-Ad2F
plus CT when compared to mice i.n. immunized with
adjuvanted Hcβtre (Figure 3A). The numbers of Ag-spe-
cific IgA AFCs in head and neck LNs (HNLNs), submaxil-
lary glands (SMGs), spleens, Peyer's patches (PPs), and
intestinal lamina propria (iLP) were similar to mice
immunized with either Hcβtre-Ad2F or Hcβtre (Figure
3A). Only minimal Ag-specific IgA AFCs were detected
in mice i.m. immunized with our Hcβtre-based vaccines
(Figure 4A). Analysis of Ag-specific IgG AFC responses
in i.n.-dosed mice exhibited elevated AFCs in HNLNs,
SMG, spleen, and PPs (p ≤ 0.05) of mice that received
adjuvanted Hcβtre-Ad2F when compared with mice
given Hcβtre (Figure 3C). The presence of Hcβtre-spe-
cific IgG AFCs was detected in NALT and NPs in both
groups of i.n.-vaccinated mice, but these were not statisti-
cally significant (Figure 3C). Mice i.m. immunized with
Hcβtre-Ad2F plus CT showed increased levels of Ag-spe-
cific IgG AFCs in the peripheral LNs (PLNs), PPs (p ≤
0.001), and HNLNs (p ≤ 0.05) in contrast to mice that
received Hcβtre plus CT (Figure 4C). Minimal IgA AFC
responses were detected in any of the lymphoid tissues
examined (Figure 4A). From these studies, we showed
Figure 1 Nasal or i.m. immunization with Hcβtre-Ad2F induces 
enhanced serum IgG and mucosal IgA anti-Hcβtre Ab responses. 
BALB/c mice were immunized by the (A,B) i.n. or (C,D) i.m. route with 
equimolar concentrations of Hcβtre (25 μg) or Hcβtre-Ad2F (50 μg), ei-
ther alone or with combination with cholera toxin (CT), as a mucosal 
adjuvant, on days 0, 7, and 14. Sera and fecal extracts were collected at 
weekly intervals beginning on day 14 post-primary immunization. Fe-
cal IgA (A,C) and serum IgG (B,D) Ab titers against Hcβtre were deter-
mined by ELISA. The addition of vaccine-targeting molecule, Ad2F, in 
the absence and the presence of CT, improved mucosal Ab responses 
when compared to mice immunized with Hcβtre only. Without adju-
vant, both groups induced weak IgG Abs responses. Data are ex-
pressed as mean ± SEM of three different experiments (n = 15 mice). *, 
p ≤ 0.001; **, p ≤ 0.05 represent the significant differences in IgA and 
IgG anti-Hcβtre levels between mice immunized with Hcβtre-Ad2F 
and Hcβtre with or without CT.
Figure 2 Nasal immunization with Hcβtre-Ad2F plus CT stimu-
lates an enhanced nasal wash secretory (S)-IgA and elevated se-
rum IgG1 and IgG2a anti-Hcβtre Ab titers. (A) BALB/c mice were 
nasally immunized with Hcβtre-Ad2F or Hcβtre plus CT, as described in 
Figure. 1. Three weeks after final immunization, S-IgA Ab levels in nasal 
washes were determined by ELISA. Mice vaccinated nasally with 
Hcβtre-Ad2F + CT showed significantly greater levels of Hcβtre-specif-
ic S-IgA when compared with mice nasally dosed with Hcβtre + CT. 
Data represent the mean ± SEM (n = 15 mice). *, p ≤ 0.001 represent 
the statistical differences in Hcβtre-specific S-IgA Abs between mice 
immunized with Hcβtre-Ad2F + CT vs. mice immunized with Hcβtre + 
CT. Serum IgG subclass anti-Hcβtre Ab responses on day 35 from (B) i.n. 
and (C) i.m. immunized mice (n = 7 mice/group) with Hcβtre-Ad2F or 
Hcβtre plus CT were evaluated. Significant elevations in (B,C) IgG1 and 
(C) IgG2a Ab titers were observed by the Hcβtre-Ad2F plus CT-immu-
nized mice versus the Hcβtre plus CT-immunized mice: *, p ≤ 0.001.
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enhances IgA AFC responses in NP and NALT and IgG
AFC responses in HNLNs, SMG, spleen, and PPs when
compared with adjuvanted Hcβtre. In addition, these data
show that i.m. immunization with Hcβtre-Ad2F in pres-
ence of CT enhances the number of IgG AFCs in PLNs,
HNLNs, and PPs when compared to mice immunized
with Hcβtre plus CT.
Hcβtre-based vaccines elicit a mixed Th cell response
Since immunization with our Hcβtre-based vaccines
induced elevated Ag-specific Ab responses in both
mucosal and systemic tissues, it was important to exam-
ine the nature of Th cells that support these Hcβtre-spe-
cific B cell responses. Splenic, HNLN, and mesenteric LN
(MLN) lymphocytes from mice dosed with adjuvanted
Hcβtre and Hcβtre-Ad2F vaccines were restimulated
with Hcβtre and subsequently evaluated for the produc-
tion of IFN-γ, IL-4, IL-5, IL-10, and IL-13 by cytokine
ELISPOT method. Analysis of Th1 and Th2 cytokine
production by Ag-stimulated T cells revealed a varied Th
cell phenotype. For i.n.-immunized mice, splenic IL-5 and
IL-10 cytokine-forming cells (CFCs) were induced to
similar levels for both vaccine groups, but increased IFN-
γ and IL-13 CFCs were observed in Hcβtre-immunized
mice and IL-4 in Hcβtre-Ad2F-dosed mice (Figure 5A). In
the HNLNs, the IFN-γ, IL-4, IL-5, and IL-13 were partic-
ularly enhanced in Hcβtre-vaccinated mice (Figure 5B).
In the MLNs, the levels of IL-4, IL-5, and IL-10 CFCs
were significantly greater than in Hcβtre-Ad2F-dosed
mice (Figure 5C). For i.m.-immunized mice, splenic IFN-
γ, IL-4, IL-5, and IL-10 CFCs (Figure 6A), HNLN IL-4, IL-
5, IL-10, and IL-13 CFCs (Figure 6B), and MLN IFN-γ,IL-
4, and IL-5 CFCs (Figure 6C) were significantly elevated
in the Hcβtre-Ad2F-immunized group when compared
to Hcβtre-immunized mice. These results showed that
Figure 3 Nasal immunization with Hcβtre-Ad2F plus CT enhances 
(A) IgA AFC responses in nasal passages (NPs) and NALT and (C) 
IgG AFC responses in head and neck LNs (HNLNs), submaxillary 
glands (SMGs), spleens, and Peyer's patches (PPs) when com-
pared with Hcβtre plus CT. Four weeks post-primary immunization, 
mononuclear cells from selected lymphoid tissues were evaluated by 
using B cell ELISPOT assay to determine the number and distribution 
of (A,C) Hcβtre-specific and total (B,D) IgG and IgG AFCs. Data are ex-
pressed as mean ± SEM of three separate experiments (n = 15 mice) of 
AFC/1 × 106 lymphocytes. *, p ≤ 0.001; **, p ≤ 0.05 represents the sta-
tistical differences in number of IgA and IgG AFCs in individual tissues 
between mice immunized with Hcβtre-Ad2F and Hcβtre with CT.
Figure 4 I.m. immunization with Hcβtre-Ad2F plus CT enhances 
the number of IgG AFCs in peripheral LNs (PLNs) HNLNs, and PPs 
when compared to mice immunized with Hcβtre plus CT. Four 
weeks post-primary immunization, mononuclear cells from selected 
lymphoid tissues were examined using B cell ELISPOT assay to deter-
mine the number and distribution of (A, C) Hcβtre-specific and (B, D) 
total IgA and IgG AFCs. Data are expressed as mean ± SEM of three sep-
arate experiments (n = 15 mice) of AFC/1 × 106 lymphocytes. *, p ≤ 
0.001; **, p ≤ 0.05 represents the significant differences in number IgG 
AFCs in individual tissues between mice immunized with Hcβtre-Ad2F 
and Hcβtre with CT.
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ited an enhanced Th2 cell bias as opposed to mice immu-
nized with Hcβtre plus CT that elicited a mixed Th cell
response. I.m. immunization with either vaccine com-
bined with adjuvant showed mixed Th cell responses. For
either immunization route, it was evident that the IgG1
Ab responses were supported by elevations in Th2 cell
cytokines and IgG2a Ab responses supported by IFN-γ.
Mouse neutralization assay
To evaluate the protective Ab responses, serum samples
from the various i.n. immunization groups were tested
for their ability to neutralize native BoNT/B. Three
sources of sera were assessed: (i) sera from unimmunized
mice; (ii) sera from mice vaccinated with Hcβtre plus CT;
and (iii) sera from mice vaccinated with Hcβtre-Ad2F
plus CT. Mice were immunized four times on days 0, 7,
14, and 21, and serum samples were collected on day 57
post-primary immunization, at which time endpoint
titers were determined for Hc/B. Mice given either
Hcβtre or Hcβtre-Ad2F showed elevated serum IgG
responses against Hc/B, while naive sera showed no reac-
tivity (Table 1). Sera samples were incubated with 2.0
LD50 of the BoNT/B at room temperature for 60 min
before i.p. injection into naïve BALB/c mice. All mice
given naive sera succumbed to intoxication by 24 h (Table
1). Mice given BoNT/B plus pooled sera from mice
nasally immunized with either adjuvanted Hcβtre or
Hcβtre-Ad2F survived. These studies demonstrated that
immunization with Hcβtre-Ad2F or Hcβtre could elicit
neutralizing Abs that protect against systemic challenge.
Discussion
Botulism results from absorption of the toxin into the
systemic circulation from either a mucosal surface or a
wound. BoNT intoxication is typically attributed to oral
ingestion of contaminated food either with the toxin or
bacteria producing the toxin [6]. Although natural expo-
sure via the inhalational route is unlikely [18], illicit aero-
sol releases have occurred [28]; thus, there is a
Figure 5 Cytokine responses by i.n.-immunized mice with Hcβtre 
and Hcβtre-Ad2F plus CT show enhanced Th1-and Th2-type cell 
responses. Three weeks after final immunization total lymphocytes 
from (A) spleens, (B) HNLNs, and (C) MLNs of Hcβtre plus CT-or Hcβtre-
Ad2F plus CT-immunized mice were isolated and cultured with Hc/B, 
OVA, or media only for 2 days, and then CFC responses were measured 
by cytokine-specific ELISPOT. Immune lymphocytes were evaluated 
for IFN-γ, IL-4, IL-5, IL-10, and IL-13 CFCs/1 × 106 lymphocytes. Data rep-
resent the mean ± S.E.M. of three experiments (n = 15 mice). p ≤ 0.001; 
**, p ≤ 0.05.
Figure 6 Cytokine responses by i.m.-immunized mice with 
Hcβtre and Hcβtre-Ad2F plus CT show enhanced Th1-and Th2-
type responses. Three weeks after final immunization, total lympho-
cytes from (A) spleens, (B) HNLNs, and (C) MLNs of Hcβtre plus CT-or 
Hcβtre-Ad2F plus CT-immunized mice were isolated and cultured with 
Hc/B, OVA, or media only for 2 days, and then CFC responses were 
measured by cytokine-specific ELISPOT. Immune lymphocytes were 
evaluated for IFN-γ, IL-4, IL-5, IL-10, and IL-13 CFCs/1 × 106 lympho-
cytes. Data represent the mean ± S.E.M. of three experiments (n = 15 
mice). p ≤ 0.001; **, p ≤ 0.05.
Table 1: 24 h Survival status in BoNT/B-mouse 
neutralization assaya.
Vaccination Groupb Sera Titerc %Survivald p-valuee
Naïve 0 0 -
Hcβtre/B + CT 19.5 ± 0.5 100 < 0.05
Hcβtre-Ad2F + CT 19.8 ± 0.2 100 < 0.05
a Pooled sera from nasally vaccinated or naive mice incubated for 
1 h with 2.0
LD50 of BoNT/B in PBS-0.2% gelatin and then injected into naive 
mice.
b Source of sera used.
c Endpoint titer for Hc/B in pooled sera (10 mice/group).
d Survival of BoNT/B-challenged mice after 24 h.
e p-value determined by Kaplan-Meier method.
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aid in conferring protection by neutralizing the toxin at
the mucosal surface. While most studies have focused on
BoNT/A [13,29,30], few studies have evaluated BoNT/B-
based vaccines [31,32]. Since BoNT/B is often implicated
in human illness, the present study focuses on generating
a protective mucosal vaccine.
Efforts to develop an efficacious vaccine for botulism
are warranted because the current pentavalent toxoid
vaccine has a number of disadvantages [23], including the
limited ability to stimulate mucosal Abs when given par-
enterally [30] and the required yearly boosts to maintain
protective Ab levels [13]. To address these shortcomings,
recombinant vaccine approaches would best preserve
neutralization epitopes, and consideration of mucosal
immunization approaches may best serve to induce both
mucosal and systemic immunity. Immunization of both
mucosal and systemic immune compartments could then
facilitate the clearance of the toxin from tissues and
inhibit its absorption to mucosal surfaces [31,33].
Current efforts to develop BoNT vaccines have focused
primarily on immunizing with recombinant Hc polypep-
tides capable of evoking protective immunity against
BoNT challenge [10,12,34,35]. Hc is an efficient immuno-
gen that combined with the ability to penetrate the epi-
thelial membranes raises the possibility that the Hc can
serve as a mucosal vaccine against botulism. Further-
more, as previously shown for protection against BoNT/
A [23] and suggested by others [36], the entire Hc frag-
ment is not required for protection and can be further
reduced to contain the C-terminal β-trefoil subdomain.
Our previous study provided the first evidence the
Hcβtre fragment retains its immunogenicity and protec-
tive capacity when delivered nasally [23]. In addition,
since β-trefoil structure is conserved among the seven
BoNTs, it is plausible this conserved structure can evoke
cross-reactive Abs against the other serotypes. In addi-
tion, we sought to develop a second animal model for
BoNT intoxication using antisera developed in rabbits.
When testing commercially prepared Hc against Hcβtre/
A-Ad2F in rabbits formulated with CT or a non-toxin
adjuvant, we found the Hcβtre/A-Ad2F vaccine was
superior to Hc in conferring protection against BoNT/A
challenge in a mouse neutralization assay when using
antisera developed in rabbits (manuscript in prepara-
tion). These results suggest that the Hcβtre-Ad2F immu-
nogen is effective in eliciting BoNT-specific Abs.
While next generation vaccines may significantly
improve vaccine efficacy, these are often poorly immuno-
genic when applied mucosally [33]. To enhance their
immunogenicity, vaccines would require an effective
adjuvant to bolster protective immunity. Currently, a
major obstacle to adapting mucosal vaccines for humans
is the lack of a mucosal adjuvant suitable for use in
humans. Nasal application of adenovirus-based vaccines
offers one approach to stimulate robust systemic and
mucosal Ab responses, as well as cell-mediated immunity
[25]. In fact, recombinant adenovirus bearing the Hc
transgene has been shown to effectively stimulate neu-
tralizing Abs to BoNT/C [37]. However, one concern lim-
iting the use of adenoviral vaccine vectors is that
preexisting immunity to adenoviruses induced by natural
exposure can potentially neutralize adenoviral vaccines
via reactivity against its hexon protein [24], thus, prevent-
ing the development of a protective immune response
[38]. Admittedly, studies have shown that i.n. immuniza-
tion seems to avoid the stimulation of systemic neutraliz-
ing Abs [39]. However, another concern is the possible
retrograde uptake of replication-deficient adenovirus
vectors into the olfactory bulb [24], suggesting perhaps a
natural consequence of wild-type Ad infection. Although
adenoviruses have been found in the CNS, they are not
generally considered as "neurotropic" and isolation of
them from brain tissues is rare [40].
To circumvent such concerns, efforts were focused on
developing a targeting moiety to enable mucosal vaccina-
tion based upon the adenovirus adhesin or F protein
instead of the whole virus. In support of our previous
study against BoNT/A [23], our current results clearly
demonstrated that the inclusion of the targeting mole-
cule, Ad2F, also boosts the levels of mucosal IgA and sys-
temic IgG Abs against serotype B when administrated
mucosally (Figure 1A,B). Moreover, it is important to
emphasize that in the absence of CT adjuvant, nasal
immunization with our recombinant Ad2F fusion vaccine
stimulated similar levels of fecal IgA Abs as in mice co-
immunized with CT (Figure 1A). In the absence of the
Ad2F targeting moiety, Hcβtre induced only a weak
mucosal Ab response even with CT. These findings sug-
gest perhaps Ad2F possesses adjuvant-promoting proper-
ties, which, in turn, could limit the use of adjuvants and
diminish the number of immunizations required to stim-
ulate protective immunity. Current studies are addressing
such possibilities. Interestingly, our study showed that
mice given our fusion vaccine via the i.m. route produced
elevated levels of both mucosal IgA and systemic IgG Abs
(Figure 1C,D). Notably, i.m. immunization with Hcβtre-
Ad2F in the absence of CT showed elevated IgG Ab titers
that remained elevated for at least 35 days post-primary
immunization. One possible explanation for our findings
could be attributed to the interactions between Ad2F and
the coxsackie adenovirus receptor, which is expressed in a
wide range of cell types. This interaction may allow more
effective delivery of the vaccine into the cells. In addition,
similar to our previous study [23], the Hcβtre's immuno-
genicity was markedly improved by the addition of Ad2F
(Figures 1, 2, 3 and 4). However, only a low level of
mucosal Abs after day 35 was observed (Figure 1C), sug-
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when the Ad2F-based vaccine was given parenterally.
Since very few IgA AFCs were detected in any of the lym-
phoid tissues of i.m.-immunized mice (Figure 4A), such
evidence suggests that transient IgA Ab responses were
induced during immunization.
Few studies have evaluated whether Th1 or Th2 cells
are beneficial for optimal Ab production for the Hc-based
vaccines. A recent study by Kobayashi et al. [30] suggests
that BoNT/A-specific Abs induced by mucosal BoNTox-
oid immunization are mediated via Th2-type cytokines.
Herein this report, a combination of Th cell types sup-
ports the BoNT/B-specific Ab responses (Figures 5 and
6). Notable enhancements in Th2-type cells were
detected in the spleens and MLNs of i.n. Hcβtre-Ad2F
plus CT-immunized mice (Figure 5A,C), and likewise for
i.m. Hcβtre-Ad2F plus CT-immunized mice (Figure
6A,C) suggesting these responses supported the
observed, elevated IgG1 Ab responses (Figure 2B,C).
These findings further corroborate the results of our pre-
vious study showing that the Hcβtre/A vaccine for
BoNT/A also elicits a mixed Th cell response [23].
Nasal administration of Hcβtre-based vaccines induced
significant systemic and mucosal Abs. To assess their pro-
tective efficacy, a mouse neutralization assay, was per-
formed (Table 1). Our data showed that passively
administered sera from animals immunized with Hcβtre
or with Hcβtre-Ad2F protected 100% mice for 24 hr
against 2.0 LD50, suggesting neutralizing Abs are induced.
Conclusion
As previously shown for Hcβtre/A [23], the Hcβtre/B is
also very immunogenic capable of eliciting elevated
serum IgG and mucosal IgA Abs, especially when geneti-
cally fused to the adhesin, Ad2F. These enhanced Ab
responses are supported by mostly by Th2 cell responses
when Hcβtre-Ad2F is given nasally, and a mixed Th1/Th2
cell response is obtained subsequent i.m. immunization.
The induced Abs were able to neutralize BoNT/B as evi-
dent in the mouse neutralization assay. Thus, these stud-
ies demonstrate that the Hcβtre immunogen can be used
as a BoNT vaccine.
Methods
Protein expression and purification
The strategy for the construction and expression of the
recombinant proteins in Pichia pastoris was similar to
those previously described [23]. A synthetic gene encod-
ing for Hc/B amino acids E786 to E1291 (Genebank ID
6030102) was designed for expression P. pastoris taking
into account the yeast P. pastoris taking into account the
yeast codon bias, the reduction of C. botulinum A/T con-
tent, and the necessity for not depleting any particular
tRNA pools. The Hcβtre/B spans from position E1071 to
E1291, as predicted by others [22]. To clone the Hcβtre
domain, we included seven more amino acids upstream
from the predicted Hcβtre beginning with E1071 to
E1291 to facilitate proper folding of the relevant domain.
To clone the Hc/B gene into the expression vector, the
synthetic gene encoding for Hc/B was amplified with
primers containing EcoRI and KpnI restriction sites.
Likewise, to clone the Hcβtre, this gene was amplified
from the synthetic Hc/B using primers containing EcoRI
and KpnI restriction sites. In both cases, the 5' primers
containing the EcoRI site also provided an ATG initiation
codon embedded into an optimal Kozak's sequence. The
PCR products were cloned into a pCR2.1 TOPO TA clon-
ing vector (Invitrogen Corp., Carlsbad, CA), excised with
EcoRI and KpnI, and cloned into the P. pastoris expres-
sion vector pPICZ B cut with EcoRI and KpnI. Such a
vector was designed to provide a C-terminal histidine tag
for subsequent protein purification. Ad2 fiber was ampli-
fied from genomic Ad2 DNA, as previously described
[23], expressing only the C-terminal domain, G378 to
E582, to include a short stretch of amino acids rich in Gly,
the region containing the trimerizing domain and the
region containing the globular knob domain, which is
important for interacting with the coxsackievirus/adeno-
virus receptor on the cell surface [41].
To generate the Hcβtre/B-Ad2F, Hcβtre was amplified
with primers generating EcoRI and SalI ends cloned and
excised with EcoRI and SalI. The mentioned region of
Ad2F was amplified with primer generating SalI and KpnI
ends, cloned, and excised with the corresponding
enzymes. The vector pPICZ B was cut with EcoRI and
KpnI. Finally, Hcβtre-Ad2F was assembled via a tri-par-
tite ligation. Primers were designed to allow in-frame
junction between the different components and the for-
mation of a flexible joint between Hcβtre and the Ad2F.
These constructs were transformed into P. pastoris by
electroporation.
Recombinant proteins in P. pastoris were purified fol-
lowing standard manufacturer's protocols. Following cul-
ture in YNB-methanol for 36-48 hr, cells were then
harvested by centrifugation, and the pelleted biomass was
disrupted with a bead-beater in ice. Debris was cleared by
centrifugation, followed by filtration through a 1.2 μm pre
filter, then by filtration through a 0.45 μm filter under
vacuum. The cleared supernatant was then applied to a
Talon column (BD Biosciences), as per the manufac-
turer's instruction. Purified proteins were eluted, titrated,
and loaded onto a 12% polyacrylamide gel. Recombinant
Hcβtre proteins were analyzed by Coomassie-stained
SDS-PAGE to assess the quality of the protein.
Immunization
BALB/c mice (National Cancer Institute) between 6 and 8
weeks old were maintained in the Montana State Univer-
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ditions in individually ventilated cages under HEPA-
filtered barrier conditions; sterile food and water were
provided ad libitum. The mice were free of bacterial and
viral pathogens, as determined by Ab screening and his-
topathologic analysis of major organs and tissues. All ani-
mal care and procedures were in accordance with
institutional policies for animal health and well-being and
approved by MSU Institutional Animal Care and Use
Committee.
Vaccines were administered by the intranasal (i.n.) or
intramuscular (i.m.) route. For i.n. immunization, mice
were given equimolar amounts of Ag corresponding to 25
μg of Hcβtre or 50 μg of Hcβtre-Ad2F and, in some
instances as stated, given with 5 μg of cholera toxin (CT;
List Biological Laboratories), as indicated, and boosted
with their respective vaccines on days 7 and 14 after ini-
tial immunization with 2 μg of CT. For i.m. immuniza-
tion, mice received 25 μg of Hcβtre or 50 μg of Hcβtre-
Ad2F with or without 1 μg of CT on days 0, 7, and 14.
Measurement of anti-Hcβtre Abs titers by ELISA
Endpoint Ab titers in serum, fecal extracts, and nasal
washes generated to Hcβtre/B were determined by the
standard ELISA methods [23]. Serum and fecal samples
were collected weekly; nasal washes, on day 35 upon
study termination, from each mouse were assessed for
their Hcβtre-specific Ab activity. Fecal extractions and
nasal washes were performed, as previously described
[23]. Flat-bottom, 96-wells (MaxiSorb, Nunc) were coated
with recombinant Hcβtre/B (5 μg/ml) and incubated at
4°C overnight, followed by washing with phosphate-buff-
ered saline (PBS) containing 0.05% Tween 20 (wash buf-
fer). The plates were blocked with 1% bovine serum
albumin (BSA) in PBS for 1 h at 37°C. After washes, serial
dilutions of serum or fecal samples in PBS containing
0.05% Tween 20 and 0.5% BSA were added to the plates
and incubated at 4°C overnight. IgG, IgG subclasses, and
IgA titers were determined using peroxidase-conjugated
goat anti-mouse IgG, IgG1, IgG2a, IgG2b, or IgA (South-
ern Biotechnology Associates). Following 90 min of incu-
bation at 37°C and the washing step, 2,2'-azinobis(3-
ethylbenthiazoline-6-sulfonic acid; Moss) was added as a
substrate, and the plates were incubated for an additional
60 min at 25°C. The endpoint titers were the reciprocal
dilutions of the last dilution yielding an absorbance at
OD415 above 0.100 OD units above negative controls.
Lymphocyte isolation
Lymphocytes were isolated from nasal passages (NPs),
submaxillary glands (SMGs), nasal-associated lymphore-
ticular tissue (NALT), small intestinal lamina propria
(iLP), Peyer's patches (PPs), mesenteric lymph nodes
(MLNs), spleens, peripheral LNs (PLNs), and head and
neck LNs (HNLNs). PPs, MLNs, spleens, PLNs, NALT,
and HNLNs were subjected to dounce homogenization,
and resulting cell suspensions were filtered through Nitex
(Fairview Fabrics), washed with complete medium (CM),
and centrifuged. Mononuclear cells from NPs, SMGs,
and iLP were isolated, as previously described [42]. Lym-
phocyte viability was > 95% from each tissue, as deter-
mined by trypan blue exclusion.
Ab ELISPOT
The B cell ELISPOT assay was used to quantify the num-
bers of IgA and IgG Ag-specific Ab-forming cells (AFCs).
Mixed cellulose ester membrane-bottomed microtiter
plates (MultiScreen-HA; Millipore) were coated at 100
μl/well with sterile PBS containing 5 μg/ml of recombi-
nant Hc/B. For total IgA or IgG AFC determinations,
wells were coated with 5 μg/ml goat anti-mouse IgG or
IgA Abs (Southern Biotechnology Associates) in sterile
PBS and incubated overnight at 25°C. The plates were
blocked with 200 μl/well of RPMI 1640 medium supple-
mented with 10% FBS (RPMI-FBS) for 1 h at 37°C. Block-
ing medium was discarded, and 100 μl of cells from each
tissue at varying concentrations were added to each well.
After incubation overnight at 37°C in a humidified cham-
ber under 5% CO2, the plates were washed with PBS con-
taining 0.05% Tween-20 followed by overnight incubation
with 100 μl/well of 1.0 μg/ml HRP conjugates of goat anti-
mouse IgG or IgA Abs (Southern Biotechnology Associ-
ates). Wells were washed, and substrate solution contain-
ing 3-amino-9-ethyl-carbazole was added. After 20-30
min, the reaction was stopped by rinsing water. AFCs
were enumerated by counting using a dissection micro-
scope (Leica).
Cytokine ELISPOT
Total splenic, HNLN, and MLN mononuclear cells (5 ×
106/ml) were resuspended in CM and restimulated with
10 μg/ml recombinant Hc/B, OVA (tissue-culture grade;
Sigma-Aldrich), or media in the presence of 10 U/ml
human IL-2 (PeproTech) for 2 days at 37°C. Cells were
washed and resuspended in CM. Stimulated lymphocytes
were then evaluated by IFN-γ, IL-4, IL-5, IL-10, and IL-
13-specific ELISPOT assays [23]. Cell suspensions were
prepared at 2 different densities: 2.4 × 105 and 8 × 104
cells ml. ELISPOT plates (MultiScreen-HA; Millipore)
were coated overnight with the desired anti-cytokine cap-
ture antibody at 25°C. Antibodies were removed, and
plates were blocked with 200 μl/well of CM for 1 h at
37°C. Cell suspensions were added in triplicate to each
well, and the plates were allowed to incubate at 37°C, 5%
CO2 for 24 h. Plates were washed with PBS containing
0.05% Tween-20, and biotinylated antibodies for either
IFN-γ, IL-4, IL-5, IL-10, or IL-13 (BD Pharmingen) were
added, and plates were incubated overnight at 4°C. After
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peroxidase-labeled anti-biotin Ab (Vector Laboratories)
at 25°C. The plates were washed again and developed by
incubating for 45 min with substrate solution containing
3-amino-9-ethyl-carbazole, followed by rinsing in tap
water. Spots were counted using a dissection microscope
(Leica).
Mouse neutralization assay
For the mouse neutralization assay, groups of mice were
immunized on days 0, 7, 14, and 21 with equimolar doses
of Hcβtre or Hcβtre-Ad2F with CT. Another group was
left unimmunized. Ab titers against Hcβtre/B and Hc/B
were determined for all groups of mice. To assess the col-
lected immune sera pooled from each vaccinated group,
on day 57, 50 μl of pooled sera from each immunization
group were diluted 1:2 in PBS containing 0.2% gelatin,
incubated for 1 h at room temperature with 2.0 mouse
LD50 of BoNT/B (1.0 × 108 MLD50/mg, Lot no. B041709-
01; Metabiologics), and then injected i.p. into five naïve
BALB/c mice. Mice were observed hourly for signs of
BoNT intoxication, and when signs of neuromuscular
weakness become obvious, animals were euthanized in
accordance with AAALAC guidelines.
Statistical Analysis
To evaluate differences among variations in Ab titers, Ab
AFCs, and cytokine CFCs, an ANOVA followed by
Tukey's method was used and discerned to the 95 percent
confidence interval. The Kaplan-Meier method (Graph-
Pad Prism, GraphPad Software, Inc., San Diego, CA) was
applied to obtain the survival fractions following intoxi-
cation with BoNT/B. Using the Mantel-Haenszel log rank
test, the P-value for statistical differences among surviv-
ing BoNT/B challenge from sera obtained from Hcβtre
plus CT-or Hcβtre-Ad2F plus CT-vaccinated mice and
naive mice were discerned at the 95 percent confidence
interval.
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